Pharm Exec's 2020 Pipeline Report
Refreshing the biologic pipeline 2020 | Nature Biotechnology
Meet The New Teva: 8% Global Generics Share, 300 ANDAs, 1,500 Launches :: Scrip
Celltrion FDA warning causes headache for Teva's biologics ambition
Teva Stock Offers Maximum Optimism For Investors (NYSE:TEVA) | Seeking Alpha
Teva's (TEVA) NDA for Schizophrenia Drug Gets FDA Acceptance
EX-99.1
Sosei see Teva pipeline cull as an opportunity -
EX-99.1
FDA nods for Teva, J&J signal pipeline progress - MM+M - Medical Marketing and Media
SymBio Pharmaceuticals : Pipeline : Treakisym® SyB L-0501
Teva-Takeda joint venture divests certain assets in Japan to Nichi-Iko - Pharmaceutical Technology
Teva Pharmaceuticals Near 20-Year Lows (NYSE:TEVA) | Seeking Alpha
The Teva Advantage
Teva's (TEVA) NDA for Schizophrenia Drug Gets FDA Acceptance
Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults ADDING MULTIMEDIA | BioSpace
Teva's drug pipeline could contain blockbusters - Globes
EX-99.1
Teva's pursuit of J&J boosted by FDA acceptance of filing for approval of long-acting schizophrenia drug | FiercePharma
A Look at Teva's Generic Drugs Research Pipeline
Drug pipeline: 4Q18 | Nature Biotechnology
Tear Sheet: Teva Pharmaceuticals Faces Pressure From Competing Generics, Seeks to Delever Quickly After Actavis Acquisition - Reorg
Teva Pharmaceutical: Generic Market Access to Global Healthcare Industry | IntechOpen
FDA approves first generic version of epilepsy drug Sabril from Teva
Producing Quality Products | Teva Pharmaceuticals
